Date:	2022101	4
Your Nar	ne:	Ruizhi Hou
Manuscr	ipt Title:	MicroRNA-543 controls pancreatic cancer development by LINC00847-microRNA-543-STK31
axis		
Manuscr	ipt numb	er (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
0	testimony		
	testimony		
_			
7	Support for attending	None	
	meetings and/or travel		
8	Patents planned, issued or	None	
Ū	pending		
	pending		
9	Participation on a Data	None	
9	Safety Monitoring Board or		
	Advisory Board		
- 10			
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

The author has no conflicts of interest to declare.

# Please place an "X" next to the following statement to indicate your agreement:

Date:	_202210	14
Your Na	me:	Jun Wei
Manusc	ript Title	MicroRNA-543 controls pancreatic cancer development by LINC00847-microRNA-543-STK31
axis		
Manusc	ript num	ber (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding,	None	
	provision of study materials, medical writing, article		
	processing charges, etc.) No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	None	
	any entity (if not indicated in item #1 above).		
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
0	testimony		
	testimony		
_			
7	Support for attending	None	
	meetings and/or travel		
8	Patents planned, issued or	None	
Ū	pending		
	pending		
9	Participation on a Data	None	
9	Safety Monitoring Board or		
	Advisory Board		
- 10			
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

The author has no conflicts of interest to declare.

# Please place an "X" next to the following statement to indicate your agreement:

Date:	202210	<u>14</u>		
Your Nar	me:	<u>Chao</u>	Wang	
Manuscr	ript Title	: <u>Micro</u>	RNA-543	controls pancreatic cancer development by LINC00847-microRNA-543-STK31
axis				
Manuscr	ript num	ber (if	known):_	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	Time frame: Since the initialNoneNone	planning of the work
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
0	testimony		
	testimony		
_			
7	Support for attending	None	
	meetings and/or travel		
8	Patents planned, issued or	None	
Ū	pending		
	pending		
9	Participation on a Data	None	
9	Safety Monitoring Board or		
	Advisory Board		
- 10			
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

The author has no conflicts of interest to declare.

# Please place an "X" next to the following statement to indicate your agreement:

Date:	20221014			
Your Nar	me:ź	Zihui	Meng	
Manuscript Title: MicroRNA-543 controls pancreatic cancer development by LINC00847-microRNA-543-STK3				
axis				
Manuscr	ipt numbe	er (if kn	lown):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
0	testimony		
	testimony		
_			
7	Support for attending	None	
	meetings and/or travel		
8	Patents planned, issued or	None	
Ū	pending		
	pending		
9	Participation on a Data	None	
9	Safety Monitoring Board or		
	Advisory Board		
- 10			
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

The author has no conflicts of interest to declare.

# Please place an "X" next to the following statement to indicate your agreement:

Date:	2022101	4
Your Nai	me:	Duqiang Luo
Manuscr	ript Title:	MicroRNA-543 controls pancreatic cancer development by LINC00847-microRNA-543-STK31
axis		
Manuscr	ript numb	er (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
0	testimony		
	testimony		
_			
7	Support for attending	None	
	meetings and/or travel		
8	Patents planned, issued or	None	
Ū	pending		
	pending		
9	Participation on a Data	None	
9	Safety Monitoring Board or		
	Advisory Board		
- 10			
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

The author has no conflicts of interest to declare.

# Please place an "X" next to the following statement to indicate your agreement:

Date:	2022101	1
Your Na	me:	Xiaoling Zhao
Manusci	ript Title:	MicroRNA-543 controls pancreatic cancer development by LINC00847-microRNA-543-STK31
axis	_	
Manusci	ript numb	er (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	Time frame: Since the initialNoneNone	planning of the work
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
0	testimony		
	testimony		
_			
7	Support for attending	None	
	meetings and/or travel		
8	Patents planned, issued or	None	
Ū	pending		
	pending		
9	Participation on a Data	None	
9	Safety Monitoring Board or		
	Advisory Board		
- 10			
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

The author has no conflicts of interest to declare.

# Please place an "X" next to the following statement to indicate your agreement:

Date:	2022101	4
Your Nar	ne:	Yan Liu
Manuscr	ipt Title:	MicroRNA-543 controls pancreatic cancer development by LINC00847-microRNA-543-STK31
axis		
Manuscr	ipt numb	er (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	
4	Consulting fees	None	

5       Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events      None         6       Payment for expert testimony      None         7       Support for attending meetings and/or travel      None         8       Patents planned, issued or pending      None         9       Patticipation on a Data Safety Monitoring Board or Advisory Board      None         10       Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid      None         11       Stock or stock options      None         12       Receipt of equipment, materials, drugs, medical writing, gifts or other services      None         13       Other financial interests      None				
lectures, presentations, speakers bureaus, manuscript writing or educational events				
speakers bureaus, manuscript writing or educational events	5	Payment or honoraria for	None	
manuscript writing or educational events		lectures, presentations,		
educational events		speakers bureaus,		
educational events		-		
6       Payment for expert testimony				
testimony	6		None	
7       Support for attending meetings and/or travel      None         8       Patents planned, issued or pending      None         9       Participation on a Data Safety Monitoring Board or Advisory Board      None         10       Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid      None         11       Stock or stock options      None         12       Receipt of equipment, materials, drugs, medical writing, gifts or other services      None         13       Other financial or non-      None	0			
meetings and/or travel		testimony		
meetings and/or travel	_			
8       Patents planned, issued or pending	7		None	
pending		meetings and/or travel		
pending				
pending				
pending				
pending	0	Patents planned issued or	Nono	
9       Participation on a Data Safety Monitoring Board or Advisory Board      None         10       Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid      None         11       Stock or stock options      None         12       Receipt of equipment, materials, drugs, medical writing, gifts or other services      None         13       Other financial or non-      None	0			
Safety Monitoring Board or Advisory Board		pending		
Safety Monitoring Board or Advisory Board				
Advisory Board	9		None	
10       Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid      None         11       Stock or stock options      None         11       Stock or stock options      None         12       Receipt of equipment, materials, drugs, medical writing, gifts or other services      None         13       Other financial or non-      None				
in other board, society, committee or advocacy group, paid or unpaid		Advisory Board		
committee or advocacy	10	Leadership or fiduciary role	None	
group, paid or unpaid      None         11       Stock or stock options      None         12       Receipt of equipment, materials, drugs, medical writing, gifts or other services      None         13       Other financial or non-      None		in other board, society,		
11       Stock or stock options      None         12       Receipt of equipment, materials, drugs, medical writing, gifts or other services      None         13       Other financial or non-      None		committee or advocacy		
11       Stock or stock options      None         12       Receipt of equipment, materials, drugs, medical writing, gifts or other services      None         13       Other financial or non-      None		group, paid or unpaid		
12     Receipt of equipment, materials, drugs, medical writing, gifts or other services    None       13     Other financial or non-    None	11		None	
materials, drugs, medical writing, gifts or other services				
materials, drugs, medical writing, gifts or other services				
materials, drugs, medical writing, gifts or other services	12	Possint of aquinment	Nono	
writing, gifts or other services	12			
services       13     Other financial or non-  None				
13 Other financial or nonNone				
	10			
financial interests	13		None	
		financial interests		

The author has no conflicts of interest to declare.

# Please place an "X" next to the following statement to indicate your agreement: